已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa

医学 大疱性表皮松解症 皮肤病科 人口 疾病 儿科 内科学 环境卫生
作者
Adam Raymakers,Aaron S. Kesselheim,Arash Mostaghimi,William B. Feldman
出处
期刊:JAMA Dermatology [American Medical Association]
卷期号:160 (3): 297-297 被引量:3
标识
DOI:10.1001/jamadermatol.2023.5857
摘要

Importance New gene therapies can offer substantial benefits to patients, particularly those with rare diseases who have few therapeutic options. In May 2023, the US Food and Drug Administration (FDA) approved the first topical gene therapy, beremagene geperpavec (B-VEC), for treating both autosomal recessive and autosomal dominant dystrophic epidermolysis bullosa (DEB). However, FDA approval was based on limited data in patients with autosomal dominant disease, even though they comprise approximately 50% of all DEB cases. Objective To estimate projected spending in the US on B-VEC therapy for treating autosomal recessive and autosomal dominant DEB. Design, Setting, and Participants This economic evaluation used data from the National Epidermolysis Bullosa Registry to estimate the current population of US patients with autosomal dominant and autosomal recessive DEB, with the aim of estimating US spending on B-VEC therapy from an all-payers perspective during 1- and 3-year periods after FDA approval. A base-case cost of $300 000 per patient per year was assumed based on a report from the manufacturer (Krystal Biotech). Exposure Treatment with B-VEC. Main Outcomes and Measures Estimated overall spending on B-VEC in the first year and over a 3-year period after FDA approval. Several prespecified sensitivity analyses with different assumptions about the eligible patient population and the cost of therapy were performed, and lifetime total costs of treatment per patient were estimated. Results The estimated number of US patients with DEB who were eligible for treatment with B-VEC in the first year after FDA approval was 894. The estimated total expenditure for B-VEC therapy was $268 million (range, $179 million-$357 million). Over a 3-year period, estimated spending was $805 million (range, $537 million-$1.1 billion). Estimated lifetime total costs per patient were $15 million (range, $10 million-$20 million) per patient with autosomal recessive DEB and $17 million (range, $11 million-$22 million) for patients with autosomal dominant DEB. Conclusions and Relevance Results of this economic evaluation suggest that the FDA’s broad indication for the use of B-VEC in treating both autosomal recessive and autosomal dominant DEB will have significant implications for payers.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
手术刀完成签到 ,获得积分10
刚刚
2秒前
7秒前
zeice完成签到 ,获得积分10
10秒前
黯然完成签到 ,获得积分10
15秒前
16秒前
辛勤晓旋完成签到,获得积分10
17秒前
欣喜的代容完成签到 ,获得积分10
18秒前
桐桐应助吃饭采纳,获得10
27秒前
28秒前
superbanggg完成签到,获得积分10
30秒前
畅快的谷秋完成签到 ,获得积分10
32秒前
32秒前
34秒前
小布发布了新的文献求助10
37秒前
休休完成签到,获得积分10
39秒前
39秒前
乐之完成签到 ,获得积分10
40秒前
41秒前
不安毛豆完成签到,获得积分10
42秒前
笨笨十三完成签到 ,获得积分10
43秒前
与我常在发布了新的文献求助10
43秒前
轻松乾发布了新的文献求助10
43秒前
斯文起眸发布了新的文献求助10
45秒前
尤静柏完成签到,获得积分10
46秒前
48秒前
jim完成签到,获得积分10
49秒前
Jasper应助Rosie采纳,获得10
50秒前
50秒前
好运h完成签到 ,获得积分10
50秒前
云氲完成签到 ,获得积分10
51秒前
思源应助doctor_loong采纳,获得10
52秒前
53秒前
吃饭发布了新的文献求助10
54秒前
Charon发布了新的文献求助10
54秒前
58秒前
赋成完成签到 ,获得积分10
58秒前
1分钟前
大东东发布了新的文献求助10
1分钟前
1分钟前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Foreign Policy of the French Second Empire: A Bibliography 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3146637
求助须知:如何正确求助?哪些是违规求助? 2797945
关于积分的说明 7826268
捐赠科研通 2454478
什么是DOI,文献DOI怎么找? 1306280
科研通“疑难数据库(出版商)”最低求助积分说明 627692
版权声明 601522